Another CAR-T therapy for treating multiple myeloma and a Chikungunya virus vaccine are the latest investigational products to secure a hard-to-obtain place on the European Medicines Agency’s PRIME scheme for getting treatments for unmet medical need to patients faster.
CT053, the CAR-T therapy that CARsgen Therapeutics is developing, and Emergent BioSolutions’s CHIKV virus-like particle (VLP) were both...








